Move Starts To Strip Anticancer Drug Regulation From FDA After New Charges It Is Delaying INDs
In Brief: NCI Needs To Move Quicker On Funding Jot New Leads, Rauscher Says; Harley Dirks Quits
Frederick RFP Held Up; NCI Probably Will Reject Any Further Delay
Moloney Convinces Most NCAB Members Of Virus Program Value, Shubik Only Dissenter
King Tells Centers To Concentrate On Project Grants
First Lady Helps Dedicate New MDA Facilities
Disease Oriented Programs Must Be Coordinated: Rabson
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - Oncologist Rachna Shroff endows award to outlast her cancer diagnosis
“Because of my health, I have a profound desire to see this endowment come to fruition now” - Michael Caputo appointed to President’s Cancer Panel
The cancer survivor and political operative says his appointment signals Trump’s interest in cancer, survivorship - KRAS pioneer and Stephenson Prize winner Frank McCormick aims to prevent all KRAS cancers with a pill
- From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - Letai: MCEDs are a “great ideal”—alas, the data don’t support widespread use
“Projecting sub-ideal tests across a large population can cause harm,” Letai says, as Galleri cruises toward FDA approval
